Biobehavioral intervention for young adult testicular cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the feasibility and acceptability of a novel intervention called Goal-focused Emotion-Regulation Therapy (GET) aimed at improving distress symptoms and emotional regulation in young adult testicular cancer survivors. Participants will be randomly assigned to receive either GET or Individual Supportive Listening over six sessions within eight weeks. The study will measure psychological outcomes such as depressive and anxiety symptoms, emotion regulation, and goal navigation skills at multiple time points. Additionally, biomarkers related to stress will be assessed to evaluate the intervention's impact on physical health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 to 39 years at time of consent
* A confirmed diagnosis of testis cancer (any stage)
* Completion of chemotherapy for testis cancer within 4 years prior to consent
* A score of \>4 on the Distress Thermometer
* English fluency, as per medical record documenting preferred language or in the judgment of the investigator
* Spanish fluency, as per medical record documenting preferred language or in the judgment of the investigator
* Able to perform informed consent

Exclusion Criteria:

* Lifetime history of psychiatric of cognitive disturbance as per self-report or medical record
* In the judgment of the consenting professional, is unable to provide informed consent and complete study sessions and assessment
* As per self-report, has medical conditions that affect the immune system and would confound immune evaluation (e.g., autoimmune disorder, inflammatory disease; uncontrolled thyroid disease; active infection; myocardial infarction or stroke in the last 6 months; Type I diabetes; acute hepatitis; recent vaccination for viral disease)
* Regular smoker (daily use)

Where it's running

• University of California, Irvine
  Irvine, California, United States Recruiting

Study contacts

• Principal investigator: Michael A Hoyt, PhD — University of California, Irvine
• Study coordinator: Michael A Hoyt, PhD
• Email: mahoyt@uci.edu
• Phone: 949-824-5281

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Primary retroperitoneal lymph node surgery versus chemotherapy for good‑prognosis metastatic testicular cancer

  This study will test whether primary RPLND (surgery) instead of standard chemotherapy leads to fewer side effects and better quality of life for men 18 and older with good‑prognosis metastatic testicular cancer.

  Recruiting Sahlgrenska University Hospital · Gothenburg, Göteborg · NCT07498959

• Sodium thiosulfate to protect hearing during cisplatin therapy in adults with solid tumors

  This study tests Pedmark sodium thiosulfate to see if it reduces hearing loss in adults receiving standard cisplatin chemotherapy.

  Recruiting Phase 1/2 University of Arizona · Tucson, Arizona · NCT07407582

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• How retroperitoneal lymph node dissection affects urination and sexual function

  This project will see if retroperitoneal lymph node dissection (RPLND) for testicular cancer changes urination, ejaculation, erections, and quality of life in adult men.

  Recruiting Jagiellonian University · Krakow, Malopolska · NCT06954233

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.